- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06057662
Personalized Comprehensive Diabetes Support for Children With Newly Diagnosed Type 1 Diabetes
Effect of Personalized Comprehensive Diabetes Support Among Families of Children With Newly Diagnosed Type 1 Diabetes
The goal of this clinical trial is to learn if access to a diabetes coach improves quality of life (QOL) for families of children with newly diagnosed type 1 diabetes. The main questions it aims to answer are:
- Determine if there are beneficial effects on diabetes-related QOL at the end of the 6-month intervention.
- Determine if potential beneficial effects persist beyond completion of the support intervention, as measured by diabetes-related QOL at 12 months and 24 months following diagnosis
Participants assigned to the intervention group will have access to a diabetes coach for 6 months following type 1 diabetes diagnosis. They will be compared to participants who are assigned to the control group and are receiving usual care.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- University of California Davis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Families of children 16 years of age or younger with a new diagnosis
- Stable living situation such that the same caregivers are anticipated to be caring for the child during the full 2-year study duration.
Exclusion Criteria:
- Families of children older than 16 years
- Children from non-English speaking families
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
|
|
Active Comparator: Intervention
personalized comprehensive diabetes support for 6 months following type 1 diabetes diagnosis
|
personalized comprehensive diabetes support
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diabetes Distress Scale
Time Frame: 24 months
|
The Distress Scale (DDS) uses a 6-point Likert scale to quantify diabetes-related stress.
Scores can range from 0 to 72.
A higher score indicates higher distress.
|
24 months
|
Problem Areas in Diabetes (PAID)
Time Frame: 24 months
|
The Problem Areas in Diabetes (PAID) uses a 6-point Likert scale to quantify diabetes-related stress.
Scores can range from 0 to 100.
A higher score indicates higher distress.
|
24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2059749
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on personalized comprehensive diabetes support
-
Taipei Medical UniversityCompleted
-
Vanderbilt University Medical CenterCompletedDiabetes MellitusUnited States
-
University Hospital, LilleNational Cancer Institute, France; Centre Oscar Lambret; University of Lille...TerminatedTumor | Oncologic DisordersFrance
-
University of ChicagoAmerican Diabetes AssociationCompleted
-
Syracuse VA Medical CenterUS Department of Veterans AffairsCompletedEmotional Stress | Psychological Stress | Life StressUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedNon-Small Cell Lung CancerUnited States
-
The University of Hong KongRecruitingCancer | LungHong Kong
-
Chinese University of Hong KongCompleted
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)Completed
-
Northwell HealthPatient-Centered Outcomes Research InstituteCompletedType 2 Diabetes Mellitus | Type 2 DiabetesUnited States